The clinical benefits associated with rituximab therapy in patients with B-cell lymphomas or autoimmune diseases are well established. Rituximab has been hypothesized to act by promoting elimination of B cells, but in this Review the authors propose another theory to explain how this agent works in autoimmune diseases—the immune-complex decoy hypothesis.
- Ronald P Taylor
- Margaret A Lindorfer
